CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Toxicities Associated with CAR-T Cell Therapies.
Toxicities Associated with CAR-T Cell Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体（CAR）T细胞疗法改善了复发/难治性B细胞淋巴瘤、B细胞急性淋巴细胞白血病和多发性骨髓瘤患者的结局。然而，CAR-T 细胞疗法也伴有特有毒性，可导致发病和死亡。大量研究现已界定CAR-T 细胞疗法相关的不同毒性，并部分阐明其机制。特别是，细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）是CAR-T 细胞输注后发生的两种主要急性毒性。其他CAR-T 相关毒性则在输注后较晚发生，包括B细胞再生障碍、低丙种球蛋白血症、感染和血细胞减少。感染是接受CAR-T 细胞疗法患者中观察到的非复发性死亡的主要原因。第二原发恶性肿瘤较罕见，主要为髓系恶性肿瘤。
Chimeric antigen receptor (CAR) T-cell therapy has improved the outcomes of patients with relapsed/refractory B-cell lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma.
However, CAR-T cell therapy is also associated with distinct toxicities that contribute to morbidity and mortality. A large number of studies now define the different toxicities associated with CAR-T cell therapy and have, in part, clarified their mechanisms. In particular, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the two main acute toxicity events that occur after CAR-T cell infusion.
Other CAR-T-related toxicities occur later after CAR-T cell infusion and include B-cell aplasia, hypogammaglobulinemia, infections, and cytopenias. Infections represent the main cause of non-relapse death observed in patients undergoing CAR-T cell therapy. Second primary malignancies are rare and are mainly represented by myeloid malignancies.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
